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1. Introduction
Throughout history tuberculosis (TB) has been a health problem for humanity. In the beginning
of civilization, when human population densities were sparse, this disease may have been
fairly harmless. However, with the increase in population densities, probably from the 17th to
19th centuries, TB took epidemic proportions [1].
Bacille Calmette Guérin (BCG) is effective to prevent miliary and meningeal TB in infants [1].
The reports about the efficacy of this vaccine for the prevention of adults pulmonary TB are
contradictory and the consensus is that the protection conferred by BCG against this form of
TB is questionable [1]. The wide use of BCG vaccination has been unable to prevent nearly two
million deaths associated with TB that are produced every year. Currently the World Health
Organization no longer recommends BCG vaccination in children born from HIVpositive
mothers which complicate the implementation of BCG vaccination programs [2]. The imple‐
mentation of standard drug treatment for TB is difficult in the areas of the highest incidence
of the disease. Treatment is further complicated by the limited effectiveness of the current
therapeutic schemes against drug resistant strains of TB [3-5].
Nowadays there is an increasing realization of the need for new animal models to test vaccine
efficacy in more realistic scenarios, overcoming the limitations of current models in use. In
addition, the elucidation of the significance of antibody-mediated defense against intracellular
pathogens, in particular against Mycobacterium tuberculosis, constitutes an exciting new
approach to improve the rational design of new vaccines, therapies and diagnostics.
© 2013 Acosta et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Specific antibodies: Players in the defense against TB
In order to develop improved vaccines and new methods for controlling TB, an important
element is the discovery of markers to measure the effectors’ mechanisms of the protective
immune response against M. tuberculosis.
For many years Cell-Mediated Immunity (CMI) was viewed as the exclusive defense mecha‐
nism against intracellular pathogens. The Th1/Th2 classical paradigm prevailed for a long time
and the development of vaccines followed this theory [6]. Based on this theory, only intracel‐
lular pathogens could be effectively controlled by granulomatous inflammation induced by a
Th1 response, whereas a Th2 response induces antibody production that controls extracellular
pathogens and parasites. However, the question of what constitutes a true demarcation
between “extracellular and intracellular” pathogens is important in this regard. During their
infectious cycle, intracellular pathogens could be found in the extracellular space and vice
versa. In the specific case of M. tuberculosis, it can be localized extracellularly at the beginning
of the infection in the upper respiratory tract as well as during advanced stages of the disease,
after rupture of granulomatous lesions occur [7]. This facultative intracellular pathogen was
shown to have an extracellular phase [7] [8] that may include replication [7] which in turn
could potentially be targeted by specific antibodies.
There are several prokaryotic and eukaryotic intracellular pathogens for which antibody have
been shown to modify the course of infection by different mechanisms, as reviewed extensively
by Casadevall and colleagues [9, 10, 11]. In the case of Erhlichia spp., specific antibodies were
shown to mediate protection [12], possibly by blocking cellular entry or promoting the
expression of proinflammatory cytokines. [13,14]. A combination of both humoral and cellular
immune mechanisms could be the optimal choice controlling certain intracellular patho‐
gens,.In this regard, de Valliere and colleagues reported that human antimycobacterial
antibodies enhanced Cell-Mediated Immune responses to mycobacteria that are beneficial to
the host [15].
3. Epidemiological evidence of antibody mediated protection
There is accumulating evidence, in the last few decades, regarding the effect of antibodies in
the context of development of pulmonary or disseminated TB. Children with low serum IgG
against sonicated mycobacterial antigens and LAM, or those who could not mount antibody
responses to these antigens were predisposed to dissemination of M. tuberculosis [16].
M. leprae reactive salivary IgA antibodies were suggested to be important in a mucosal
protective immunity [17]. In study carried out among the Mexican Totonaca Indian population,
the presence of high antibody titers to Ag87 complex antigens were observed in patients with
non-cavitary TB and in patients who were cured with anti-TB chemotherapy. In contrast,
patients without such antibodies had a poor outcome of the disease [18].
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4. Experimental studies
4.1. Animal models
An important criterion for the evaluation of the role of specific antibodies in the protection
against TB is the use of animal models. Currently, there is no optimal model to re-produce the
infection as it occurs in humans [19].
The geographical location, genetic factors of the host, the presence of environmental myco‐
bacteria and other concomitant infections like helminthiasis, are factors that have to be
considered when designing animal experiments [20]. Several animal models have been used
to evaluate different aspects of mycobacterial infection and disease. A crucial aspect is the
delivery of mycobacterial inoculum. In this regard, several routes of inoculation have been
employed experimentally, including intravenous, intraperitoneal, intranasal, intratracheal
and aerosol [21, 22].
The study of the distribution of monoclonal and polyclonal antibody formulations in different
organs and tissues of mice after administration by different routes, including the use of
backpack models have been reported [23-27]. Each model has its advantages and drawbacks.
For example, the backpack model is very useful for the evaluation of the protective role of IgA,
but poses ethical problems in long term experiments due to the increase in tumour size over
time produced by the inoculated hybridoma [28]. In prophylactic and therapeutic models,
antibody formulations have been administered via the intranasal [29], intravenous [30] and
intraperitoneal [26] routes and combined with cytokines and antibiotics [31, 32] before and/or
after the infectious challenge. The administration of M. tuberculosis pre-coated with antibodies
[27, 33] in different models of infection has also contributed to understanding the interactions
between host and microbe.
Another approach has been the use of knockout mice models for IgA [34] polymeric immu‐
noglobulin receptor (pIgR) [34] and B cells [35,36,37,38], as will be discussed later.
4.2. Experimental studies with antibodies
A substantial number of studies utilizing anti mycobacterial antibodies have been conducted
as far back as the end of the 19th century. These experiments can be grouped into several
categories: serum therapies, mouse polyclonal antibodies, human polyclonal antibodies
(including commercial human gamma globulins), secretory human IgA (hsIgA) and studies
with monoclonal antibodies.
4.2.1. Serum therapies
Serum therapy experiments were conducted from the second half of the 19th century (reviewed
in [39,40]). Immune sera was generated by immunizing animals with different mycobacterial
fractions and administered either to animals or humans [39,40] The results obtained were either
beneficiary, variable, inconclusive or contradictory, [39,40]. These variable results led to the
perceived minor role of antibodies in the defense against M. tuberculosis.
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What factors could have led to the heterogeneity in study results? Recognizable differences in
the methods used for serum preparations and their administration, as well as the lack of
appropriate experimental controls probably accounted in part for the studies outcomes.
Furthermore, it is important to recognize that immune serum is a polyclonal preparation that
includes antibodies with multiple specificities and isotypes. Consequently, polyclonal sera
may contain antibodies of different subclasses and functional categories that can affect
theoutcome of infection. For example, IgG3 murine monoclonal antibodies protected against
M.tuberculosis [27] but failed to protect against Cryptococcus neoformans [41]. An IgG3 non-
protectivemonoclonal antibody to C. neoformans, became protective upon subclass switching
to IgG1 [41]. In addition to intrinsic factors associated with the antibody structure, other
parameters such as the genetic background of the microbe and the immunocompetence of the
host could alter the outcome of antibody protection experiments.
For some microorganisms, such as Samonella typhimurium and C. neoformans, passive antibody
therapy efficacy depends on the mouse strain used [42, 43]. In the same way, some microbial
strains are more susceptible to the effects of antibodies [44].
The animal model used is another important parameter that varies between different experi‐
ments cited in the literature [45]. Timing, the route of infection, the magnitude of the infecting
inoculum are some additional variables that could affect antibody protection studies [46].
Despite their variability, the results obtained with serum therapy were valuable, demonstrat‐
ing some beneficial effect of serum on the course of TB in humans, mainly in cases of early or
localized TB [45]. Moreover, it was demonstrated that long periods of treatment were necessary
to achieve a sustained effect [45].
4.2.2. Polyclonal mouse antibodies
A recent study re-examined the usefulness of immune serum in the context of a therapeutic
vaccine against TB [32]. This vaccine, named RUTI, is generated from detoxified M. tuberculo‐
sis cell fragments that facilitate a balanced T helper response to a wide range of antigens along
with intense antibody production [47]. Local accumulation of specific CD8+ T cells and a strong
humoral response after immunization are characteristic features of RUTI that contribute to its
protective properties. In that study, immune serum was generated by immunizing mice with
RUTI [32]. Severe Combined Immunodeficiency (SCID) mice were inoculated with M.
tuberculosis and treated with chemotherapy for 3–8 weeks. After chemotherapy they were
treated for up to 10 weeks with intraperitoneal injections of the generated immune serum. Mice
treated with immune serum from RUTI vaccinated animals showed significant decreases in
lung CFU in addition to reduced extent of granulomatous response and abscess formation [47].
These results indicate that protective serum antibodies can be elicited by vaccination, and that
antibodies may be usefully combined with chemotherapy [32, 47, 48].
4.2.3. Human gammaglobulins
4.2.3.1. Specific human polyclonal antibodies
Evidence for the stimulatory role of specific polyclonal antibodies on cellular immunity in
experimental mycobacterial infections was reported by de Valliere and colleagues in 2005 [15].
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In this study, serum samples containing specific antimycobacterial antibodies were obtained
from volunteers vaccinated twice with BCG by the intradermal route. Significant titres of IgG
antibodies against lipoarabinomannan (LAM) were detected in the sera. BCG internalization
into phagocytic cells was significantly increased in the presence of these BCG induced
antibodies as were the growth inhibitory effects of neutrophils and macrophages on myco‐
bacteria. Furthermore, these antibodies induced significant production of IFN-γ by CD4+ and
CD8+ T cells [15].
4.2.3.2. Commercial immunoglobulin formulations
Human Intravenous Immunoglobulin (IVIG) has been used to treat individuals with immune
deficiencies and patients with inflammatory, autoimmune and infectious conditions [49, 50,
51]. Several groups tested the effect of human immunoglobulin preparation on mycobacterial
infection. Roy and colleagues showed that treatment of M. tuberculosis infected mice with one
cycle of IVIG led to the substantially lower bacterial loads in the spleen and lungs following
its administration either at early or at late stage of infection 52]. The effect of the administration
of a commercial preparation of human immunoglobulin (hIg) in a mouse model of intranasal
infection with BCG was evaluated by Olivares and colleagues [33]. This group demonstrated
the passage of specific antibodies to saliva and lung lavage following the intranasal or
intraperitoneal administration of human hIg to mice. This treatment inhibited BCG coloniza‐
tion of the lungs of treated mice. A similar inhibitory effect was observed after infection of
mice with hIg -opsonized BCG [33].
The same formulation was evaluated also in a mouse model of intratracheal infection with M.
tuberculosis. Animals receiving human hIg intranasally 2h prior to intratracheal challenge
demonstrated a significant decrease in lung bacillary load as compared with non-treated
animals [29]. When M. tuberculosis was pre-incubated with hIg prior to challenge the same
effect was observed [29].
The protective effect of the hIg formulation was abolished following pre-incubation with M.
tuberculosis [29]. These results are suggestive of a potential role for specific human antibodies
in the defense against mycobacterial infections.
Taken together, these studies provide support for the potential use of immunoglobulins
against M. tuberculosis.
4.2.3.3. Human secretory IgA
Human secretory IgA (hsIgA) is the major class of antibody associated with immune protection
of the mucosal surfaces [53]. Colostrum volume is above 102 mL in humans during the first
three days after delivery [54]. The high percentage of (hsIgA) in human colostrum [55] strongly
suggests its important role in passive immune protection against gastrointestinal and respi‐
ratory infections [56]. In one study performed by Alvarez and colleagues, hsIgA from human
colostrum was obtained by anion exchange and gel filtration chromatographic methods, using
DEAE Sepharose FF and Superose 6 preparative grade, respectively [57].
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hsIgA was administered intranasally to BALB/c mice, and the level of this immunoglobulin in
several biological fluids was determined by ELISA. The results showed the presence of this
antibody in the saliva of animals that received the hsIgA, at all time intervals studied. In
tracheobronchial lavage, hsIgA was detected at 2 and 3 hours after inoculation in animals that
received the hsIgA [58]. Similar studies were performed by Falero and colleagues with
monoclonal antibodies of IgA and IgG class [59]. Following demostration that hsIgA could be
detected in several biological secretions after intranasal administration, the protective effect
of this formulation against M. tuberculosis challenge was evaluated. Mice challenged with M.
tuberculosis preincubated with hsIgA showed a statistically significant decrease in the mean
number of viable bacteria recovered from the lungs compared to control mice and to the group
that received the hsIgA before challenge with M. tuberculosis. Moreover, an increased level of
iNOS production was also reported (Alvarez et al., mannuscript in preparation). Consistently
with this result, a better organization of granulomatous areas with foci of lymphocytes and
abundant activated macrophages were observed in the lungs of mice that received M.
tuberculosis pre-incubated with hsIgA and sacrificed at 2 months postchallenge. Untreated
animals, however, showed an increased area of bronchiectasis and atelectasis as well as fibrin
deposits, accumulation of activated macrophages and lymphocytes.
The pneumonic areas were more prominent in the untreated animals than in the groups treated
with hsIgA and M. tuberculosis pre-incubated with hsIgA (Alvarez et al., manuscript in
preparation)
4.2.4. Monoclonal antibodies
Since the first report on the use of the monoclonal antibody Mab 9d8 against M. tuberculosis
[27], many similar studies have been reported [40]. This IgG3 monoclonal antibody (Mab)
generated against arabinomannan (AM) capsular polysaccharide, increased the survival of
intratracheally infected mice when the M. tuberculosis Erdman strain was pre-coated with it
[27]. In this study, a longer survival associated with an enhanced granulomatous response in
the lungs was found as compared to controls receiving an isotype-specific non-related Mab
[27]. Another Mab, SMITB14, directed against the AM portion of LAM prolonged the survival
of intravenously infected mice associated with reduced lung CFU and prevention of weight
loss [60]. In this study, the authors demonstrated that protection was independent of the
antibody Fc portion, because the F(ab’)2 fragment also conferred a similar protective effect [60].
In another study, mice receiving the Mab 5c11 (an IgM antibody that recognizes other
mycobacterial arabinose-containing carbohydrates in addition to AM) intravenously prior to
Mannosylated lipoarabinomannan (ManLAM) administration, showed a significant clearance
of Man-LAM and redirection of this product to the hepatobiliary system [26]. This study
strongly supports an indirect effect of certain antibodies on the course of mycobacterial
infection, altering problably the pharmacokinetics of mycobacterial components and contri‐
buting to protection against TB [26].
Heparin Binding Hemagglutinin Adhesin (HBHA) is a surface-exposed glycoprotein involved
in the mycobacterial binding to epithelial cells and in mycobacterial dissemination [62].
Monoclonal antibodies 3941E4 (IgG2a) and 4058D2 (IgG3) directed against HBHA were used
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to coat mycobacteria before administration to mice. In this study, spleen CFUs was reduced
while lung CFUs did not [63]. These results suggest that binding of these antibodies to HBHA
can impede mycobacterial dissemination.
The protective efficacy of a monoclonal antibody, TBA63 and IgA anti-Acr administered
intranasally before and after the intranasal or aerosol challenge with M. tuberculosis was
demonstrated in a study by Williams and colleagues [64]. In another series of experiments
carried out by López and colleagues, the protective effect of this Mab administered intratra‐
cheally before an intratracheal challenge with virulent mycobacteria was evaluated. At 21 days
post-infection, pre-treatment of mice with TBA63 caused a significant decrease in viable
bacteria in the lungs compared to control mice or those treated with the Mab against the 38-
kDa protein (TBA86) [65]. Consistent with the reduction of viable bacteria following treatment
with TBA63, the area of peribronchial inflammation was also statistically smaller in this group
compared to the control group [65].
When the lungs of mice were histologically examined, granulomas were better organized in
the infected animals that had received TBA63 than in controls or mice treated with TBA86. The
reduction of CFU in lungs of the treated group was associated with milder histopathological
changes, as indicated by the organization of the granulomas and less pneumonic area. The fact
that this Mab promotes granuloma formation in mice infected intratracheally with M. tuber‐
culosis strongly suggests the close interaction between antibody mediated immunity and cell-
mediated immunity to induce protection against intracellular pathogens (66).
The 16 kDa protein (Acr antigen) has been defined as a major membrane protein peripherally
associated with the membrane [67] carrying epitopes restricted to tubercle bacilli on the basis
of B-cell recognition [68, 69]. The Acr antigen is present on the surface of tubercle bacilli and
is highly expressed in organisms growing within infected macrophages, allowing it to be
potentially targeted by specific antibodies either inside infected cells as well as extracellulary.
A novel immunotherapy, combining treatment with anti-IL-4 antibodies, IgA antibody against
16 kDa protein and IFN-γ, showed the potential for passive immunoprophylaxis against TB.
In genetically deficient IL-4-/- BALB/c mice, infection in both lungs and spleen was substan‐
tially reduced for up to 8 weeks. Administration of rIL-4 to IL-4-/- mice with increased bacterial
counts to wild-type levels and make mice refractory to protection by IgA/IFN-γ [70].
More recently, Balu and colleagues reported that intranasal administration of a human IgA1
Mab, obtained using a single-chain variable fragment derived from an Ab phage library with
high affinity for hspX and the human FcαRI (CD91) IgA receptor together with recombinant
mouse IFN-γ significantly inhibited pulmonary infection with M. tuberculosis H37Rv in mice
transgenic for human CD91 but not in the CD91-negative controls. These results suggested
that binding to CD91 was necessary for the IgA-imparted passive protection [71]. When the
Mab was incubated with human whole-blood or monocyte cultures it inhibited H37Rv
infection.
Inhibition of the infection by the antibody was synergistic with human rIFN-γ in purified
human monocytes cultures but not in whole blood cultures [71]. The demonstration of the role
of FcαRI (CD91) in human IgA mediated protection contributes to understanding the mecha‐
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nisms involved as well as for using this knowledge for the future development of new
immunotherapies for TB [71].
4.2.5. Transgenic mice
Mouse models with deficiency in antibody production can provide useful information for
understanding  certain  roles  of  antibodies  in  protection  against  mycobacterial  infections.
Rodríguez and colleagues reported that after immunization of IgA deficient (IgA-/-) and wild
type mice by the intranasal route with the mycobacterial surface antigen PstS-1, IgA-/- mice
were more susceptible to BCG infection than IgA+/+ mice [34]. Cytokine response analysis
demonstrated  reduction  in  the  IFN-γ  and  TNF-α  production  in  the  lungs  of  IgA-/-  as
compared with  IgA+/+  mice,  suggesting  that  IgA may play  a  role  in  protection against
mycobacterial infections in the respiratory tract. Furthermore, these authors demonstrated
that immunized pIgR-/- mice were more susceptible to BCG infection than immunized wild-
type mice [34].
In an attempt to elucidate whether antibody-mediated immunity has a special role in the
defense against TB, different experiments with B cell knockout mice were performed by several
authors. In 11016, Vordermeier and colleagues developed an infection model of TB in μ chain
knockout Ig- mice. Organs from M. tuberculosis infected IgG- mice had three to eight fold
elevated counts of viable bacilli compared with those from normal mice. This result suggested
that B cells play a role in the containment of murine tuberculous infection [35]. In another study
B cell KO mice and controls were infected by aerosol with M. tuberculosis. They were subse‐
quently given chemotherapy to destroy remaining bacilli and then re-challenged by aerosol
exposure. There were not differences in the ability of animals to control this second infection,
indicating that, in this low dose pulmonary infection model, any local production of antibodies
neither impeded nor enhanced the expression of specific acquired resistance [36].
In another series of  experiments the role of  B cells  was evaluated during early immune
responses to infection with a clinical strain of M. tuberculosis (CDC 1561). In this study, despite
comparable  bacillary  loads  in  the  lungs,  B  cell  KO  mice  had  a  less  severe  pulmonary
granuloma formation and delayed dissemination of bacteria from lungs to peripheral organs.
Additional analysis of lung cells demonstrated higher numbers of lymphocytes, particular‐
ly  CD8+  T  cells,  macrophages,  and  neutrophils  in  wild-type  and  reconstituted  mice  as
compared  with  B  cell  KO  mice.  These  results  demonstrate  that  less  severe  granuloma
formation  and  delayed  dissemination  of  mycobacteria  found  in  B  cell  KO  mice  were
dependent  on  B  cells,  (not  antibodies,  at  least  in  this  study)  and  were  associated  with
modification of cellular infiltrate in the lungs [37]. This latter result differs from a study
carried out by Maglione and colleagues in which B cell-/- mice demonstrated exacerbated
immunopathology  corresponding  with  enhanced  pulmonary  recruitment  of  neutrophils
following aerosol challenge with M. tuberculosis Erdman strain [38]. Infected B cell-/- mice
demonstrated increased production of IL-10 in the lungs, while IFN- γ, TNF-α, and IL-10R
were not significantly different from those of wild type mice [38].. B cell-/- mice demonstrat‐
ed enhanced susceptibility to aerosol infection of 300 CFU of M. tuberculosis with elevated
bacterial burden in the lungs but not in the spleen or liver [38].
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Together these studies suggest that B cells may have an important role in host defense against
M. tuberculosis.
5. Mechanisms of action
The various effects of antibodies demonstrated in the studies analyzed, suggest that different
mechanisms of action are involved in the effect of monoclonal and polyclonal antibodies on
M. tuberculosis. Secretions found on mucosal surfaces contain significant levels of Igs, partic‐
ularly, IgA. IgA has both direct and indirect functional roles for combating infectious agents
such as viruses and bacteria that cross the mucosal barrier [72]. Moreover, experimental
evidence suggests that IgA associated with the pIgR may neutralize pathogens and antigens
intracellularly during their transport from the basolateral to the apical zone of epithelial cells
[73,74]. In addition, IgA may interact with Gal-3 (an intracellular binding β-galactosidase
lectin), and interfere with the interaction of mycobacteria with the phagosomal membrane,
resulting in the decrease of bacterial survival and replication in the phagosome [75].
Antibodies may be critical, during the extracellular phases of intracellular facultative patho‐
gens. They may act by interfering with adhesion, by neutralizing toxins and by activating
complement. Moreover, antibodies may be able to penetrate recently infected cells, bind
internalised pathogens, and enhance antigen processing (76). Antibodies may also play a
crucial role in modulating the immune response by activating faster secretion of selected
cytokines that in turn, contribute to more efficient and rapid Th1 response [76,77], increasing
the efficacy of co-stimulatory signals, enhancing Antibody Dependent Cellular Cytotoxicity
(ADCC) and the homing of immune cells to the lungs after the respiratory infection [10,78, 79,
80, 81, 82, 83].
Examples of relevant potential action mechanisms of antibodies against M. tuberculosis were
discussed by Glatman-Freedman [40].
6. Potential uses of antibodies against TB
Future applications of antibody formulations for the control of TB may include several
possibilities including treatment, prevention and diagnosis.
6.1. Treatment
Antibody based therapy could potentially be useful in several scenarios. They could be used
to shorten the standard treatment period of patients with uncomplicated TB when coupled
with standard chemotherapy. However, they would be particularly important in the treatment
of patients infected with Multidrug Resistant (MDR) and Extensively Drug Resistant (XDR)
strains, in combination with the standard treatment.




Prophylactic use of antibodies could be applied in recent contacts of TB patients, with special
attention to risk groups [84]. In this regard, successful prophylactic use of antibodies in exposed
individuals has been shown in the case of several other pathogens such as varicella, tetanus,
Respiratory Synsicial Virus (RSV), rabies and Hepatitis B [85, 86]
6.3. Vaccines
The induction of specific protective antibody responses by vaccination, either alone or as an
addition to the stimulation of cell mediated immunity could be a novel strategy for the
development of new generation of prophylactic and therapeutic vaccines against TB.
The prevailing past dogma that discounted the role of antibodies in host protection against TB
has resulted in a limited study of B cell immunodominant epitopes as targets for protective
immunity [87].
6.3.1. Polysaccharide conjugate vaccines
Polysaccharide  conjugate  vaccines  are  considered  to  elicit  specific  protective  antibody
responses against a variety of pathogens [88]. However, the polysaccharide conjugate vaccine
against  Salmonella  typhi  [89]  demonstrates  the feasibility  of  this  kind of  vaccines  for  the
prevention  of  infectious  diseases  caused  by  intracellular  pathogens.  In  the  case  of  M.
tuberculosis,  several authors reported the use of polysaccharide conjugated vaccine candi‐
dates [61, 90, 91, 92].
All these vaccine candidates induced the production of specific IgG [61, 90, 91, 92] and some
of them conferred variable levels of protection [61, 91] which validate this strategy as one of
the potential avenues for the development of new generation of vaccines against tuberculosis
6.3.2. Identifying other B-cell immunodominant epitopes
With the development of bioinformatics tools for bacterial genome analysis, it has been
possible to predict in silico microbial regions that trigger immune responses relevant for
protection and vaccine development. A candidate experimental vaccine based on proteolipo‐
somes from M. smegmatis is currently in development [93].
In one study, bibliographic search was used to identify highly expressed proteins in active,
latent and reactivation phases of TB [94]. The subcellular localization of the selected proteins
was defined according to the report on the identification and localization of 1044 M. tubercu‐
losis proteins using two-dimensional, capillary high-performance liquid chromatography
coupled with mass spectrometry (2DLC/MS) method [95] and using prediction algorithms.
Taking into consideration the cell fractions potentially included in the proteoliposome, from
the previously identified proteins, the ones located in the cell membrane and cell wall, as well
as those which are secreted and homologous to those of M. smegmatis were selected.
The regions of the selected proteins containing promiscuous B and T cell epitopes were
determined [94]. Thus the M. smegmatis proteoliposomes were predicted to contain multiple
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B and T epitopes which are potentially cross reactive with those of M. tuberculosis. It is
important to note that there could be conformational B epitopes and additional epitopes related
with lipids and carbohydrates included in the proteoliposomes that could reinforce the
humoral cross reactivity.
Considering the results of the in silico analysis, proteoliposomes of M. smegmatis were obtained
and their immunogenicity was studied in mice [93]. In addition to cellular immune effectors
recognizing antigens from M. tuberculosis, cross reactive humoral immune responses of several
IgG subclasses corresponding with a combined Th1 and Th2 pattern against antigenic
components of M. tuberculosis were elicited. These findings were in concordance with the in
silico predictions [93, 94]. It is interesting to note that differences in the pattern of humoral
recognition of lipidic components was dependent on the characteristics of the adjuvant used,
which could have relevance for the development of vaccines which includes lipidic compo‐
nents [93]. Currently studies are underway to evaluate the protective capacity of M. smegma‐
tis proteoliposomes in challenge models with M. tuberculosis in mice.
Bioinformatics tools for prediction of T and B epitopes were also employed for the design of
multiepitopic constructions, which were used to obtain recombinant BCG strains. Based on
this prediction, B cell epitopes from ESAT-6, CFP-10, Ag87B and MTP40 proteins were selected
and combined with T cell epitopes of the 87B protein and fused to Mtb8.4 protein [96].
A significant IgG antibody response against specific B cell epitopes of ESAT-6 and CFP-10 was
obtained in mice immunized with the recombinant strain. After studying the specific response
of spleen cells by lymphoproliferation assay and detection of intracellular cytokines in CD4 +
and CD8 + subpopulations, the recognition of T epitopes was also observed. The response
showed a Th1 pattern after immunization with this recombinant strain (Mohamud, R, et al.
manuscript in preparation). In another series of experiments, recombinant BCG strains
expressing several combinations of multiepitopic constructions were used to immunize BALB/
c mice subcutaneously and challenged intratracheally with the M. tuberculosis H37Rv strain.
Recombinant BCG strains expressing T epitopes from 87BAg fused to Mtb8.4 protein and BCG
expressing a HSP62 T cell epitope plus different combinations of B cell epitopes from 87BAg,
Mce1A, L7/L12, 16 kDa, HBHA, ESAT6, CFP10 and MTP40 and combinations of B cell epitopes
alone produced significant reductions in lung CFU compared to BCG (Norazmi MN, et al.
manuscript in preparation).
6.3.3. Diagnosis
Although no serological assays are currently recommended for diagnosis of TB [97], largely
due to the possibility of false results and thus incorrect treatments, for many other pathogens,
serological diagnostic tests has been of great value, particularly in poor countries. In some
cases, antibody responses can constitute useful correlates of protection [98]. In the specific case
of TB, several studies of the antibody response have been reported [99]. There is a substantial
amount of variability in antibody response to TB [100]. This variability has been attributed to
several factors. Some of these factors are associated with the pathogen (strain variation, micro-
environment and growth state of bacteria) and others are related to the host, primarily previous
exposure to related antigens and host genetics [99].
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However, it is important to consider that only a small fraction of the genomic regions of M.
tuberculosis encoding proteins has been explored. Currently, novel immunoassay platforms
are being used to dissect the entire proteome of M. tuberculosis, including reacting protein
microarrays with sera from TB patients and controls [101,102]. These studies could lead to the
discovery of new antigens that may constitute suitable diagnostic markers and tools for the
identification of protection correlates.
7. Concluding remarks
The cumulative work reviewed above with regard to the use of antibody formulations and
vaccines suggest that antibodies if present at the right moment at the site of infection could
provide protection against M. tuberculosis. This concept leads the way to the development of
a new generation of vaccines. Such vaccines could work by eliciting specific IgA and/or IgG
antibodies that could recognize and intercept the pathogen at the port of entry, primarily the
mucosal surfaces, inactivating bacterial components essential for the microbial survival in
the host, activating complement for direct lysis of the cells, opsonizing bacteria to promote
their  capture  by  phagocytic  cells  and  inducing  stimulation  of  specific  cellular  immune
responses [103, 104].
Various antibody formulations could potentially be used as immunotherapeutic agents in
combination with the conventional treatment and in the management of patients affected by
Multidrug Resistant (MDR) and Extensively Drug Resistant (XDR) strains.
The study of the role of specific antibodies in the defense against tuberculosis opens new
possibilities for future development of new vaccines, diagnostics tools and therapies against
this pathogen. It is likely that new discoveries will arise from the ongoing studies in this area
that will expedite the introduction of new strategies in the fight against tuberculosis.
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